Low-fiber fruits and vegetables, lean proteins, and foods rich in omega-3 fatty acids tend to be easier on an inflamed gut, ...
Clinical outcomes for ulcerative colitis patients with a prior anti-TNF therapy failure appeared similar with ustekinumab ...
A preliminary modeling study suggests that four variables accessible at discharge could predict the risk for 90-day ...
Johnson & Johnson, a leader in immunology, has developed ARGES, a new AI-powered tool that could transform endoscopic ...
Biopharma doubles down on immunology and inflammation as companies target new pathways and seek to improve on current options ...
In a mid-stage study, the candidate itolizumab achieved 23.3% clinical remission rate at 12 weeks, numerically better than ...
About a third of ulcerative colitis patients inadequately respond to anti-TNF drugs, necessitating treatment with other biologics or with JAK inhibitors, the researchers wrote. "Further research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback